Close

Needham & Company Affirms Acadia Pharma (ACAD) at 'Buy'; Says Initial Nuplazid Sales Affected by Sampling

Go back to Needham & Company Affirms Acadia Pharma (ACAD) at 'Buy'; Says Initial Nuplazid Sales Affected by Sampling

ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results

August 4, 2016 4:07 PM EDT

Quarter highlighted by approval and launch of NUPLAZID (pimavanserin) in the United States, the first and only FDA-approved drug for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the second quarter ended June 30, 2016.

The second quarter of 2016 was highlighted by transformative events for ACADIA, including the FDA... More